From functional genomics to precision medicine: The therapeutic potential of targeting ROCK signaling in pancreatic cancer.
Venessa T Chin, Adnan Nagrial, Lorraine A Chantrill, David K Chang, Angela Chou, Jeremy Humprhis, Mark Cowley, Jiamin Wu, Renee DiPetro, Clare Watson, Calan Spielman, Angela Steinmann, Mark Pinese, Jessica Pettitt, Amber Johns, Nicola Waddell, Sean Grimmond, Paul Timpson, Andrew Victor Biankin, Marina Pajic
Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2013
e15029 Background: Pancreatic cancer (PC) is a highly lethal disease with few effective treatment options for metastatic disease. PC is a genetically highly heterogeneous disease that lends itself to a personalised approach to translational research (Biankin et al. Nature. 2012 Nov 15;491(7424):399-405.). Genomic sequence data from the Australian Pancreatic Genome Initiative (APGI) has identified a subset of patients with ROCK-1 amplification. ROCK-1 is a downstream target of Rho, a small GTPase, which is involved in cell adhesion and motility and has been shown to play a role in cancer cell growth and invasiveness (S. Boeck, P. Stieber, et al. Oncology 2006; 70:255., Lane J, Martin T et al..View full abstract